The year 2025 has been marked by turbulence in the U.S. healthcare stock market, with investors witnessing significant dips across biotechnology, insurance, and pharmaceutical equities. Yet, amid this turmoil, Fildena and other erectile dysfunction (ED) medications stand out as resilient performers. While broader pharmaceutical shares struggle, ED drugs are demonstrating remarkable stability,...